- Home
- AGEN vs GTE Comparison
AGEN vs GTE Comparison
Compare AGEN & GTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- GTE
- Stock Information
- Founded
- AGEN 1994
- GTE 2003
- Country
- AGEN United States
- GTE Canada
- Employees
- AGEN N/A
- GTE N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- GTE Oil & Gas Production
- Sector
- AGEN Health Care
- GTE Energy
- Exchange
- AGEN Nasdaq
- GTE Nasdaq
- Market Cap
- AGEN 142.8M
- GTE 139.0M
- IPO Year
- AGEN 2000
- GTE N/A
- Fundamental
- Price
- AGEN $4.55
- GTE $4.08
- Analyst Decision
- AGEN Buy
- GTE
- Analyst Count
- AGEN 2
- GTE 0
- Target Price
- AGEN $14.50
- GTE N/A
- AVG Volume (30 Days)
- AGEN 395.5K
- GTE 218.9K
- Earning Date
- AGEN 11-11-2025
- GTE 11-03-2025
- Dividend Yield
- AGEN N/A
- GTE N/A
- EPS Growth
- AGEN N/A
- GTE N/A
- EPS
- AGEN N/A
- GTE N/A
- Revenue
- AGEN $101,706,000.00
- GTE $621,677,000.00
- Revenue This Year
- AGEN $60.49
- GTE $5.03
- Revenue Next Year
- AGEN N/A
- GTE N/A
- P/E Ratio
- AGEN N/A
- GTE N/A
- Revenue Growth
- AGEN N/A
- GTE N/A
- 52 Week Low
- AGEN $1.38
- GTE $3.34
- 52 Week High
- AGEN $7.34
- GTE $8.19
- Technical
- Relative Strength Index (RSI)
- AGEN 48.05
- GTE 51.75
- Support Level
- AGEN $4.36
- GTE $3.82
- Resistance Level
- AGEN $5.20
- GTE $4.12
- Average True Range (ATR)
- AGEN 0.27
- GTE 0.16
- MACD
- AGEN 0.04
- GTE 0.02
- Stochastic Oscillator
- AGEN 40.91
- GTE 67.05
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About GTE Gran Tierra Energy Inc.
Gran Tierra Energy Inc is an independent energy company. The company, along with its subsidiaries, is focused on oil and gas exploration and production, with assets in Colombia, Canada, and Ecuador. It produces oil, natural gas, and natural gas liquids. Gran Tierra has assembled a diversified, high-quality asset base that is fully operated in Colombia and Ecuador and partly in Canada. The company operates various blocks in Colombia and Ecuador, spanning three basins. It also has contiguous areas in Alberta, Canada, spanning various gross acres across the Western Canadian Sedimentary Basin. The company's reportable segments are Colombia, Ecuador, Canada, and Other. A majority of its revenue is derived from its operations in Colombia.